CN112274687A - Stable hydrocolloid oily yarn and preparation method thereof - Google Patents

Stable hydrocolloid oily yarn and preparation method thereof Download PDF

Info

Publication number
CN112274687A
CN112274687A CN202011336914.7A CN202011336914A CN112274687A CN 112274687 A CN112274687 A CN 112274687A CN 202011336914 A CN202011336914 A CN 202011336914A CN 112274687 A CN112274687 A CN 112274687A
Authority
CN
China
Prior art keywords
parts
hydrocolloid
oily yarn
hydrocolloid oily
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202011336914.7A
Other languages
Chinese (zh)
Other versions
CN112274687B (en
Inventor
车七石
刘少辉
李新霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangzhou Rainhome Pharm and Tech Co Ltd
Original Assignee
Guangzhou Rainhome Pharm and Tech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangzhou Rainhome Pharm and Tech Co Ltd filed Critical Guangzhou Rainhome Pharm and Tech Co Ltd
Priority to CN202011336914.7A priority Critical patent/CN112274687B/en
Publication of CN112274687A publication Critical patent/CN112274687A/en
Application granted granted Critical
Publication of CN112274687B publication Critical patent/CN112274687B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
    • A61L2300/104—Silver, e.g. silver sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/21—Acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

The invention belongs to the technical field of medical materials, and particularly relates to a stable hydrocolloid oily yarn and a preparation method thereof. The stable hydrocolloid oily yarn provided by the invention comprises the following raw materials in parts by weight: the base material is reticular polyester fiber; the hydrocolloid comprises the following components in parts by weight: 7-11 parts of thermoplastic elastomer, 27-45 parts of vaseline, 6-18 parts of lanolin, 90-180 parts of liquid paraffin, 8-23 parts of sodium carboxymethylcellulose, 3-9 parts of anti-inflammatory bacteriostatic agent and 6-17 parts of tissue repair agent. The stable hydrocolloid oily yarn provided by the invention has excellent air permeability, absorbability and viscosity, has good performance of being attached to skin, can resist bacteria, diminish inflammation, stop bleeding, inhibit the formation of scars, has obvious effect of promoting wound healing, and is safe and non-irritant.

Description

Stable hydrocolloid oily yarn and preparation method thereof
Technical Field
The invention belongs to the technical field of medical materials, and particularly relates to a stable hydrocolloid oily yarn and a preparation method thereof.
Background
The medical dressing is a material for covering the wound surface and assisting the wound healing. Conventional dressings include ordinary gauze, absorbent cotton, cotton pads. The dressing has good air permeability and moisture permeability, and the cotton gauze has higher liquid absorption capacity in the use condition, so that liquid can be uniformly distributed in the whole piece of gauze to prevent the generation of local hydrops, but the dressing is easy to adhere to a wound to cause secondary damage to the wound. With the aging of socioeconomic and world population, traditional medical dressings represented by cotton gauze have difficulty meeting the requirements of the nursing process.
The hydrocolloid oily gauze is a dressing prepared by adding hydrocolloid particles into vaseline gauze, and can form gel after absorbing seepage, so that a moist wound environment is created, the hydrocolloid oily gauze is not adhered to a wound, the wound can be reduced, and the wound healing is promoted.
The hydrocolloid oily gauze in the market at present is prepared from vaseline, hydrocolloid particles, silver sulfadiazine and gauze, but does not have moisturizing and anti-inflammatory effects, and the silver sulfadiazine is unstable after being placed, so that the hydrocolloid oily gauze capable of moisturizing, diminishing inflammation and improving antibacterial stability is urgently needed.
Disclosure of Invention
In order to solve the problems in the prior art, the invention aims to provide a stable hydrocolloid oily yarn and a preparation method thereof. The hydrocolloid oily gauze with the stabilizing function provided by the invention has excellent air permeability, absorptivity, viscosity and good skin bonding performance, and the added tissue repairing agent and the anti-inflammatory bacteriostatic agent play roles in resisting bacteria and diminishing inflammation, stopping bleeding, promoting wound healing, inhibiting scar formation and improving the stability of sulfadiazine silver. The hydrocolloid oily gauze is especially suitable for various bruises, burns, bedsores and various surgical wounds.
In order to achieve the purpose, the invention provides the technical scheme that:
the invention provides a stable hydrocolloid oily yarn, which is characterized by comprising a base material and a hydrocolloid component: the base material is reticular polyester fiber;
the hydrocolloid comprises the following components in parts by weight: 7-11 parts of thermoplastic elastomer, 27-45 parts of vaseline, 6-18 parts of lanolin, 90-180 parts of liquid paraffin, 8-23 parts of sodium carboxymethylcellulose, 3-9 parts of anti-inflammatory bacteriostatic agent and 6-17 parts of tissue repair agent.
Preferably, the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate in a weight ratio of (4-9): (2-5): (1-3).
Preferably, the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate in a weight ratio of 7:2: 3.
Preferably, the anti-inflammatory bacteriostatic agent consists of silver sulfadiazine, sodium ferulate and chitosan in a weight ratio of (2-6) to (2-7) to (4-10).
Preferably, the anti-inflammatory bacteriostatic agent consists of silver sulfadiazine, sodium ferulate and chitosan according to the weight ratio of 3:5: 6.
Preferably, the thermoplastic elastomer is SEBS.
Preferably, the hydrocolloid comprises the following components in parts by weight: 9 parts of thermoplastic elastomer, 34 parts of vaseline, 12 parts of lanolin, 120 parts of liquid paraffin, 16 parts of sodium carboxymethylcellulose, 6 parts of anti-inflammatory bacteriostatic agent and 13 parts of tissue repair agent.
Preferably, the SEBS is selected from one or more of G1650, G1651 and G1652 of Kraton in the United states.
Preferably, the particle aperture of the sodium carboxymethyl cellulose is 20-150 μm.
The invention also provides a stable hydrocolloid oily yarn as described above, characterized in that it comprises the following steps:
weighing the raw materials according to the weight parts of the hydrocolloid oily yarn;
softening the thermoplastic elastomer, the liquid paraffin, the vaseline and the lanolin for 25-45min at the temperature of 100-200 ℃ to obtain a mixture;
adding the sodium carboxymethylcellulose, the anti-inflammatory bacteriostatic agent and the tissue repair agent into the mixture, mixing and stirring at the temperature of 90-125 ℃ to obtain a melt, and defoaming in vacuum;
and coating the melt after vacuum defoaming on the base material to obtain the hydrocolloid oily yarn.
The hydrocolloid oil gauze disclosed by the invention is added with a tissue repairing agent consisting of allantoin, zinc hyaluronate and calcium hyaluronate. The allantoin can promote cell growth, accelerate wound healing, promote tissue healing and cell metabolism, and is a good healing agent for skin wound. The invention unexpectedly discovers that when allantoin, zinc hyaluronate and calcium hyaluronate are combined into a tissue repair regulator according to the weight ratio of 7:2:3, the components have mutual synergistic effect, so that the wound skin tissue can be repaired, scar formation is inhibited, the hygroscopicity of the composition can be increased, a moist environment beneficial to wound healing can be provided for a wound, and the capability of absorbing biological fluid of the composition is enhanced.
The stable hydrocolloid oily gauze provided by the invention is added with the anti-inflammatory bacteriostatic agent consisting of silver sulfadiazine, sodium ferulate and chitosan. The silver sulfadiazine has strong antibacterial effect and can promote healing of wound. Experiments prove that the anti-inflammatory bacteriostatic agent consisting of the silver sulfadiazine, the sodium ferulate and the chitosan according to the weight ratio of 3:5:6 has the synergistic effect of the components, and can effectively promote the drug to permeate the skin, so that the hydrocolloid oily gauze provided by the invention can better exert the anti-inflammatory bacteriostatic effect, and effectively inhibit the generation of harmful bacteria on the surface of the skin.
Compared with the prior art, the stable hydrocolloid oily yarn provided by the invention has the following advantages:
(2) the stable hydrocolloid oily gauze provided by the invention has the effects of promoting wound healing, promoting tissue growth and inhibiting scar formation by adding the tissue repairing agent, can provide a slightly humid environment beneficial to healing for the wound, and enhances the liquid absorption capacity of the dressing; the healing time of the wound surface is obviously shortened, the adhesion between the wound and the dressing is prevented, the dressing change is painless, and the dressing change is free from irritation to the skin;
(3) the stable hydrocolloid oily yarn provided by the invention is added with the anti-inflammatory and bacteriostatic agent, has the effects of resisting bacteria, diminishing inflammation and stopping bleeding, and can inhibit the breeding of harmful bacteria on the surface of skin.
Detailed Description
The present invention is further illustrated by the following description of specific embodiments, which are not intended to limit the invention, and various modifications and improvements can be made by those skilled in the art based on the basic idea of the invention, but the invention is within the protection scope of the invention.
SBES is a styrene-ethylene-butylene-styrene block copolymer available from Kraton, usa under code number G1651.
The starting materials in the examples of the present invention are all commercially available.
Example 1 a stabilized hydrocolloid oily yarn
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
16517 parts of G, 27 parts of vaseline, 6 parts of lanolin, 90 parts of liquid paraffin, 8 parts of sodium carboxymethylcellulose, 3 parts of an anti-inflammatory bacteriostatic agent and 6 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate according to the weight ratio of 7:2: 3.
The anti-inflammatory bacteriostatic agent consists of silver sulfadiazine, sodium ferulate and chitosan according to the weight ratio of 3:5: 6. The preparation method of the stable hydrocolloid oily yarn comprises the following steps:
weighing the raw materials in parts by weight;
softening 1651 of G, liquid paraffin, vaseline and lanolin in a reaction kettle at 200 deg.C for 30 min to obtain a mixture;
and adding the sodium carboxymethylcellulose, the anti-inflammatory bacteriostatic agent and the tissue repair agent into the mixture, wherein the particle aperture of the sodium carboxymethylcellulose is 60 microns. Mixing and stirring at the rotating speed of 100r/min for 20min at the temperature of 100 ℃ to obtain a melt, and defoaming in vacuum;
coating the melt after vacuum defoaming on the reticular polyester fiber to obtain a base material net;
the specific coating process comprises the following steps: the melt was placed in a thermostatic glue bath in a two-roll coater, the temperature in the glue bath being maintained at 100 ℃. The reticular polyester fiber passes through a first coating roller which is uniformly covered with a layer of melt and is coated with a layer of melt in advance; and removing redundant melt in the mesh holes in the reticular polyester fibers by a second coating roller to obtain the base material mesh. Wherein the spacing between the two rolls was 2mm and the coating speed was 4.5 m/min.
Cooling, laminating, cutting and packaging to obtain the hydrocolloid oily yarn.
Example 2
Example 2 a stabilized hydrocolloid oily yarn
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
16519 parts of G, 34 parts of vaseline, 12 parts of lanolin, 120 parts of liquid paraffin, 16 parts of sodium carboxymethylcellulose, 6 parts of an anti-inflammatory bacteriostatic agent and 13 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate according to the weight ratio of 7:2: 3.
The anti-inflammatory bacteriostatic agent consists of silver sulfadiazine, sodium ferulate and chitosan according to the weight ratio of 3:5: 6.
The preparation method of the stable hydrocolloid oily yarn comprises the following steps:
weighing the raw materials in parts by weight;
softening 1651 of G, liquid paraffin, vaseline and lanolin in a reaction kettle at 200 deg.C for 30 min to obtain a mixture;
and adding the sodium carboxymethylcellulose, the anti-inflammatory bacteriostatic agent and the tissue repair agent into the mixture, wherein the particle aperture of the sodium carboxymethylcellulose is 60 microns. Mixing and stirring at the rotating speed of 100r/min for 20min at the temperature of 100 ℃ to obtain a melt, and defoaming in vacuum;
coating the melt after vacuum defoaming on the reticular polyester fiber to obtain a base material net;
the specific coating process comprises the following steps: the melt was placed in a thermostatic glue bath in a two-roll coater, the temperature in the glue bath being maintained at 100 ℃. The reticular polyester fiber passes through a first coating roller which is uniformly covered with a layer of melt and is coated with a layer of melt in advance; and removing redundant melt in the mesh holes in the reticular polyester fibers by a second coating roller to obtain the base material mesh. Wherein the spacing between the two rolls was 2mm and the coating speed was 4.5 m/min.
Cooling, laminating, cutting and packaging to obtain the hydrocolloid oily yarn.
Example 3
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
165111 parts of G, 45 parts of vaseline, 18 parts of lanolin, 180 parts of liquid paraffin, 23 parts of sodium carboxymethylcellulose, 9 parts of an anti-inflammatory bacteriostatic agent and 17 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate according to the weight ratio of 7:2: 3.
The anti-inflammatory bacteriostatic agent consists of silver sulfadiazine, sodium ferulate and chitosan according to the weight ratio of 3:5: 6.
The preparation of the stabilized hydrocolloid oily yarn was carried out as in example 2
Example 4
Stable hydrocolloid oily yarn
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
16519 parts of G, 24 parts of vaseline, 12 parts of lanolin, 120 parts of liquid paraffin, 16 parts of sodium carboxymethylcellulose, 6 parts of an anti-inflammatory bacteriostatic agent and 13 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate according to the weight ratio of 1:4: 5.
The anti-inflammatory bacteriostatic agent consists of silver sulfadiazine, sodium ferulate and chitosan according to the weight ratio of 3:5: 6.
The preparation of the stabilized hydrocolloid oily yarn was carried out as in example 2
Example 5A stabilized hydrocolloid oily yarn
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
16519 parts of G, 24 parts of vaseline, 12 parts of lanolin, 120 parts of liquid paraffin, 16 parts of sodium carboxymethylcellulose, 6 parts of an anti-inflammatory bacteriostatic agent and 13 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate according to the weight ratio of 7:2: 3.
The anti-inflammatory bacteriostatic agent consists of silver sulfadiazine, sodium ferulate and chitosan according to the weight ratio of 1:7: 10.
The preparation of the stabilized hydrocolloid oily yarn was carried out as in example 2
Comparative example 1
Stable hydrocolloid oily yarn
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
16519 parts of G, 34 parts of vaseline, 12 parts of lanolin, 120 parts of liquid paraffin, 16 parts of sodium carboxymethylcellulose, 6 parts of an anti-inflammatory bacteriostatic agent and 13 parts of a tissue repair agent;
the tissue repair agent consists of allantoin and zinc hyaluronate according to a weight ratio of 7: 2.
The anti-inflammatory bacteriostatic agent consists of silver sulfadiazine, sodium ferulate and chitosan according to the weight ratio of 3:5: 6.
The preparation of the stabilized hydrocolloid oily yarn was carried out as in example 2
The difference from example 2 is that calcium hyaluronate was not added to the tissue repair agent.
Comparative example 2
Stable hydrocolloid oily yarn
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
16519 parts of G, 34 parts of vaseline, 12 parts of lanolin, 120 parts of liquid paraffin, 16 parts of sodium carboxymethylcellulose, 6 parts of an anti-inflammatory bacteriostatic agent and 13 parts of a tissue repair agent;
the tissue repair agent consists of allantoin and calcium hyaluronate according to a weight ratio of 7: 3.
The anti-inflammatory bacteriostatic agent consists of silver sulfadiazine, sodium ferulate and chitosan according to the weight ratio of 3:5: 6.
The preparation of the stabilized hydrocolloid oily yarn was carried out as in example 2
The difference from example 2 is that zinc hyaluronate was not added to the tissue repair agent.
Comparative example 3
Stable hydrocolloid oily yarn
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
16519 parts of G, 34 parts of vaseline, 12 parts of lanolin, 120 parts of liquid paraffin, 16 parts of sodium carboxymethylcellulose, 6 parts of an anti-inflammatory bacteriostatic agent and 13 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and hyaluronic acid in a weight ratio of 1:1: 1.
The anti-inflammatory bacteriostatic agent consists of silver sulfadiazine, sodium ferulate and chitosan according to the weight ratio of 3:5: 6.
The preparation of the stabilized hydrocolloid oily yarn was carried out as in example 2
The difference from example 2 is that the tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate in a weight ratio of 1:1: 1.
Comparative example 4
Stable hydrocolloid oily yarn
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
16519 parts of G, 34 parts of vaseline, 12 parts of lanolin, 120 parts of liquid paraffin, 16 parts of sodium carboxymethylcellulose, 6 parts of an anti-inflammatory bacteriostatic agent and 13 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and hyaluronic acid according to the weight ratio of 7:2: 3.
The anti-inflammatory bacteriostatic agent consists of sodium ferulate and chitosan according to the weight ratio of 5: 6.
The preparation of the stabilized hydrocolloid oily yarn was carried out as in example 2
The difference from the embodiment 2 is that the anti-inflammatory bacteriostat is not added with silver sulfadiazine.
Comparative example 5
Stable hydrocolloid oily yarn
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
16519 parts of G, 34 parts of vaseline, 12 parts of lanolin, 120 parts of liquid paraffin, 16 parts of sodium carboxymethylcellulose, 6 parts of an anti-inflammatory bacteriostatic agent and 13 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and hyaluronic acid according to the weight ratio of 7:2: 3.
The anti-inflammatory bacteriostatic agent is prepared from silver sulfadiazine and sodium ferulate according to the weight ratio of 3: 5.
The preparation of the stabilized hydrocolloid oily yarn was carried out as in example 2
The difference from the embodiment 2 is that the chitosan is not added in the anti-inflammatory bacteriostat.
Comparative example 6
Stable hydrocolloid oily yarn
The embodiment provides a hydrocolloid oily yarn, and the concrete scheme is as follows:
a hydrocolloid oily yarn consisting of a substrate and a hydrocolloid component:
the base material is reticular polyester fiber,
the hydrocolloid component is prepared from the following raw materials in parts by weight:
16519 parts of G, 34 parts of vaseline, 12 parts of lanolin, 120 parts of liquid paraffin, 16 parts of sodium carboxymethylcellulose, 6 parts of an anti-inflammatory bacteriostatic agent and 13 parts of a tissue repair agent;
the tissue repair agent consists of allantoin, zinc hyaluronate and hyaluronic acid according to the weight ratio of 7:2: 3.
The anti-inflammatory bacteriostatic agent consists of silver sulfadiazine, sodium ferulate and chitosan according to the weight ratio of 1:1: 1.
The preparation of the stabilized hydrocolloid oily yarn was carried out as in example 2
The difference from the embodiment 2 is that the anti-inflammatory bacteriostat consists of silver sulfadiazine, sodium ferulate and chitosan according to the weight ratio of 1:1: 1.
Test example I, antibacterial property test
1. Test materials: examples 1-5, comparative examples 1-6.
2. Test subjects: escherichia coli, Candida albicans, Staphylococcus aureus.
3. The test method comprises the following steps: and (3) antibacterial experiment: 5cm by 5cm stabilized hydrocolloid oily yarn prepared in examples 1 to 5 and comparative examples 1 to 6 was placed in a sterile conical flask, and 70mL of phosphate buffer (0.03 mol. L.) was added thereto-1) And 5mL of bacterial liquid, after the liquid permeates into the culture medium, culturing at 37 ℃ for 24h, and then counting colonies.
The formula for calculating the bacteriostasis rate is as follows: x = (A-B)/A X100%, wherein X is the bacteriostasis rate, A is the average colony number before sample oscillation, and B is the average colony number after sample oscillation.
4. Test results
The test results are shown in table 1.
TABLE 1 Stable hydrocolloid oily yarn antimicrobial test
Figure 577496DEST_PATH_IMAGE002
The results of the antibacterial performance tests in table 1 show that the stable hydrocolloid oily gauze prepared in the embodiments 1 to 5 of the present invention has significant inhibitory effects (P > 0.05) on escherichia coli, candida albicans and staphylococcus aureus, and the antibacterial rates after 24 hours contact are all above 98%, wherein the highest antibacterial rate in the embodiment 2 is above 98%, which is the best embodiment of the present invention. The bacteriostatic effects of comparative examples 1 to 6 were relatively weak. The comparative examples 4 to 6 and the comparative examples show that the anti-inflammatory bacteriostatic agent consisting of the silver sulfadiazine, the sodium ferulate and the chitosan added in the invention has broad-spectrum and strong antibacterial performance, can effectively prevent the wound from being infected by bacteria, and has high bacteriostatic rate.
Test example three, skin repair force test
1. Test materials: stable hydrocolloid oily yarn prepared in groups 1-5 and comparative examples 1-3.
2. Test subjects: 90 female Wistar rats were selected with a body weight of 250 g.
3. The test method comprises the following steps:
90 rats were randomly divided into 9 groups of 10 rats each, examples 1-5, comparative examples 1-3, and blank.
At the beginning of the experiment, 0.25 mL/compound anesthetic (thiamine ketone) was injected into the abdominal cavity to allow the animals to enter a shallow anesthetic state, and then the area of 5cm × 5cm of hair on the back was cut. After the shearing area is disinfected, a square wound surface of 3cm multiplied by 3cm is cut at the middle part of the spine of the back of the mouse by using a surgical knife and is deep to the subcutaneous part, so that a square knife wound surface is formed.
The prepared stable hydrocolloid oily gauze of 3cm × 3cm is pasted on the wound surface of a rat, and the medicines are changed once every 3 days until the 9 th day after the wound. The wound size was measured and wound healing recorded when changing dressings.
4. And (3) test results:
the test results are shown in table 2.
TABLE 2 comparison of wound surface area (cm) at different times after injury2）
Figure 963478DEST_PATH_IMAGE004
As can be seen from Table 2, the wound surface area of the blank control group was gradually reduced in examples 1 to 5, comparative examples 1 to 3, as time passed. However, the reduction of the wound area was significantly smaller in the comparative examples 1 to 3 than in the examples 1 to 5. Compared with the wound surface areas of comparative examples 1-3, the differences of the wound surface areas of the test groups in 3 days, 6 days and 9 days have statistical significance (p is less than 0.05), and the observation shows that the granulation tissues grow in the groups of examples 1-5 on the 3 rd day after injury, thin layers or dot-and-ball-shaped epithelia grow on the local part, and the wound edge skin shrinks obviously; on day 9 after the wound, the wound surface was substantially filled with granulation tissue, and the wound margin had seen concentric growth of neoepithelium, whereas the wound surfaces of the comparative examples 1-3 had only a thin layer of granulation, and no obvious neoepithelium was seen. The stable hydrocolloid oily yarn prepared by the method can obviously promote wound healing and skin tissue regeneration.
Test example III stability test
After 1 month, 2 months, 3 months, 6 months and 12 months of the sterilized and bacteriostatic hydrocolloid oily gauze prepared in the examples 1 to 5 and the comparative examples 1 to 6 are reserved, the content of silver sulfadiazine in the hydrocolloid oily gauze is determined by high performance liquid chromatography to check the stability, and the experimental result is shown in table 3.
TABLE 3 measurement of silver sulfadiazine content (calculated as indicated)
Figure 680898DEST_PATH_IMAGE005
As can be seen from table 3, the content of silver sulfadiazine in the hydrocolloid oily gauze prepared in examples 1 to 3 was within the acceptable range after sample retention for 1 month, 2 months, 3 months, 6 months and 12 months, while the content of silver sulfadiazine in the hydrocolloid oily gauze of comparative examples 4 to 6 began to decrease greatly after 3 months, 6 months and 9 months, which indicates that the ratio of silver sulfadiazine, sodium ferulate and chitosan affects the content of silver sulfadiazine.
The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.

Claims (9)

1. A stabilized hydrocolloid oily yarn comprising a substrate and a hydrocolloid component:
the base material is reticular polyester fiber;
the hydrocolloid comprises the following components in parts by weight: 7-11 parts of thermoplastic elastomer, 27-45 parts of vaseline, 6-18 parts of lanolin, 90-180 parts of liquid paraffin, 8-23 parts of sodium carboxymethylcellulose, 3-9 parts of anti-inflammatory bacteriostatic agent and 6-17 parts of tissue repair agent.
2. The stable hydrocolloid oily yarn of claim 1 wherein said tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate in a weight ratio of (3-8): (1-4): (1-5).
3. The stable hydrocolloid oily gauze of claim 2 wherein said tissue repair agent consists of allantoin, zinc hyaluronate and calcium hyaluronate in a weight ratio of 7:2: 3.
4. The stable hydrocolloid oily yarn of claim 1 wherein said anti-inflammatory bacteriostatic agent is comprised of silver sulfadiazine, sodium ferulate and chitosan in a weight ratio of (2-6): 2-7): 4-10.
5. The stable hydrocolloid oily yarn of claim 1 wherein said anti-inflammatory bacteriostatic agent is comprised of silver sulfadiazine, sodium ferulate and chitosan in a weight ratio of 3:5: 6.
6. The stabilized hydrocolloid oily yarn of claim 1, wherein said thermoplastic elastomer is SEBS.
7. The stable hydrocolloid oily yarn of claim 1 wherein the hydrocolloid comprises the following components in parts by weight: 9 parts of thermoplastic elastomer, 34 parts of vaseline, 12 parts of lanolin, 120 parts of liquid paraffin, 16 parts of sodium carboxymethylcellulose, 6 parts of anti-inflammatory bacteriostatic agent and 13 parts of tissue repair agent.
8. Hydrocolloid oily yarn according to claim 1, characterized in that the particle size of the sodium carboxymethyl cellulose is between 20 μm and 150 μm.
9. A process for the preparation of a stabilized hydrocolloid oily yarn according to any of claims 1 to 8, characterized in that it comprises the following steps:
weighing the raw materials according to the weight portion of the hydrocolloid oily yarn of any one of claims 1 to 8;
softening the thermoplastic elastomer, the liquid paraffin, the vaseline and the lanolin for 25-45min at the temperature of 100-200 ℃ to obtain a mixture;
adding the sodium carboxymethylcellulose, the anti-inflammatory bacteriostatic agent and the tissue repair agent into the mixture, mixing and stirring at the temperature of 90-125 ℃ to obtain a melt, and defoaming in vacuum;
and coating the melt after vacuum defoaming on the base material to obtain the hydrocolloid oily yarn.
CN202011336914.7A 2020-11-25 2020-11-25 Stable hydrocolloid oil yarn and preparation method thereof Active CN112274687B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011336914.7A CN112274687B (en) 2020-11-25 2020-11-25 Stable hydrocolloid oil yarn and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011336914.7A CN112274687B (en) 2020-11-25 2020-11-25 Stable hydrocolloid oil yarn and preparation method thereof

Publications (2)

Publication Number Publication Date
CN112274687A true CN112274687A (en) 2021-01-29
CN112274687B CN112274687B (en) 2023-05-30

Family

ID=74425462

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011336914.7A Active CN112274687B (en) 2020-11-25 2020-11-25 Stable hydrocolloid oil yarn and preparation method thereof

Country Status (1)

Country Link
CN (1) CN112274687B (en)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013149323A1 (en) * 2012-04-02 2013-10-10 Ntegrity Natural products for skin care
CN103520767A (en) * 2013-10-28 2014-01-22 山东赛克赛斯药业科技有限公司 Anti-microbial healing-promoting hydrogel dressing and preparation method therefor
CN103566371A (en) * 2012-08-01 2014-02-12 南京神奇科技开发有限公司 Antimicrobial physical method
US20150118283A1 (en) * 2011-09-02 2015-04-30 BLüCHER GMBH Wound Dressing with an Antimicrobial Effect
CN105749333A (en) * 2016-04-08 2016-07-13 杭州吉为医疗科技有限公司 Medical dressing of hyaluronic acid and preparation method of medical dressing
CN105833332A (en) * 2016-06-01 2016-08-10 北京汉氏联合生物技术股份有限公司 Composite external use dressing rich in collagen and hyaluronic acid
CN108126232A (en) * 2017-12-29 2018-06-08 广州润虹医药科技股份有限公司 Hydrocolloid oil yarn and preparation method thereof
CN108136027A (en) * 2015-06-19 2018-06-08 全球健康方案有限责任公司 For the delivery system based on vaseline of active constituent
CN109122718A (en) * 2018-10-11 2019-01-04 云南省第人民医院 A kind of medical solid sterilizing new material and preparation method thereof
CN109395143A (en) * 2018-10-16 2019-03-01 广州润虹医药科技股份有限公司 A kind of antiseptic anti-adhesion hydrocolloid oil yarn and preparation method thereof
CN109498834A (en) * 2018-12-14 2019-03-22 广州润虹医药科技股份有限公司 A kind of bacteriostatic hydrocolloid dressing and preparation method thereof
CN110974999A (en) * 2019-12-18 2020-04-10 广州润虹医药科技股份有限公司 Composition for resisting bacteria and promoting wound healing and medical hydrocolloid oily yarn thereof

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150118283A1 (en) * 2011-09-02 2015-04-30 BLüCHER GMBH Wound Dressing with an Antimicrobial Effect
WO2013149323A1 (en) * 2012-04-02 2013-10-10 Ntegrity Natural products for skin care
CN103566371A (en) * 2012-08-01 2014-02-12 南京神奇科技开发有限公司 Antimicrobial physical method
CN103520767A (en) * 2013-10-28 2014-01-22 山东赛克赛斯药业科技有限公司 Anti-microbial healing-promoting hydrogel dressing and preparation method therefor
CN108136027A (en) * 2015-06-19 2018-06-08 全球健康方案有限责任公司 For the delivery system based on vaseline of active constituent
CN105749333A (en) * 2016-04-08 2016-07-13 杭州吉为医疗科技有限公司 Medical dressing of hyaluronic acid and preparation method of medical dressing
CN105833332A (en) * 2016-06-01 2016-08-10 北京汉氏联合生物技术股份有限公司 Composite external use dressing rich in collagen and hyaluronic acid
CN108126232A (en) * 2017-12-29 2018-06-08 广州润虹医药科技股份有限公司 Hydrocolloid oil yarn and preparation method thereof
CN109122718A (en) * 2018-10-11 2019-01-04 云南省第人民医院 A kind of medical solid sterilizing new material and preparation method thereof
CN109395143A (en) * 2018-10-16 2019-03-01 广州润虹医药科技股份有限公司 A kind of antiseptic anti-adhesion hydrocolloid oil yarn and preparation method thereof
CN109498834A (en) * 2018-12-14 2019-03-22 广州润虹医药科技股份有限公司 A kind of bacteriostatic hydrocolloid dressing and preparation method thereof
CN110974999A (en) * 2019-12-18 2020-04-10 广州润虹医药科技股份有限公司 Composition for resisting bacteria and promoting wound healing and medical hydrocolloid oily yarn thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MATEI， PETRUTA MIHAELA: "In Vitro Antifungal Activity of Chitosan-Polyphenol Conjugates against Phytophthora cinnamomi" *
裴继诚: "漆酶催化壳聚糖-阿魏酸接枝共聚提高产物抗氧化及抗菌性的研究" *

Also Published As

Publication number Publication date
CN112274687B (en) 2023-05-30

Similar Documents

Publication Publication Date Title
Gruppuso et al. Polymeric wound dressings, an insight into polysaccharide-based electrospun membranes
US6897349B2 (en) Silver-containing compositions, devices and methods for making
EP1216065B1 (en) Silver-containing compositions, devices and methods for making
EP1917047B1 (en) Treatment of chronic ulcerous skin lesions
Chopra et al. Strategies and therapies for wound healing: a review
CN109248333B (en) Medical dressing for resisting bacteria and promoting wound healing and preparation method and application thereof
JP5460580B2 (en) Novel active ingredients and their use in fusion
CN107617121B (en) Biological induction active dressing for skin wound surface and preparation method and application thereof
EP2617437B1 (en) Method for using hydrogel sheet for treating wound
CN107261200B (en) Chitosan-nano-laponite composite gel wound dressing and preparation method thereof
EP2844306B1 (en) Wound dressings
CN110859989B (en) Liquid band-aid and preparation method thereof
CN106110369A (en) A kind of medical composite type hyaluronic acid dressing and preparation method thereof
CN109289079B (en) Medical dressing for inhibiting scars and preparation method and application thereof
CN112245648B (en) Anti-inflammatory and antibacterial hydrocolloid oily yarn and preparation method thereof
CN108815381B (en) Traditional Chinese medicine silver titanate composite porous material for burn wound healing and preparation method and application thereof
CN114343975A (en) Wet wound dressing and its prepn
CN109432483B (en) Medical dressing for accelerating wound healing and preparation method and application thereof
Morgan Alginate dressings: part 1: historical aspects
CN112274687A (en) Stable hydrocolloid oily yarn and preparation method thereof
CN113616849B (en) Liquid dressing for external wound care and preparation method thereof
CN111481733B (en) Biological medicine wound surface dressing
US20130018334A1 (en) Biodegradable wound care products with biocompatible artificial skin treatment and healing accelerator
CN109276748B (en) Anti-adhesion healing-promoting antibacterial hydrocolloid dressing and preparation method thereof
CN111001030B (en) Medical dressing and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant